As one of the first manufacturers of N1‑Methylpseudouridine-5’-Triphosphate, TriLink provides some of the best NTPs on the market with several benefits for improved mRNA vaccine and therapeutic production.
From North America to the Asia-Pacific, our NTPs are foundational components in various vaccine programs across the globe. Our trusted modified NTPs, including N1-Methylpseudouridine-5’-Triphosphate, are the proven ideal compounds for mRNA synthesis.
TriLink’s most-requested modified NTPs, including N1‑Methylpseudouridine-5’‑Triphosphate, are readily available for off‑the‑shelf use and can be shipped globally. Our experts can also accommodate novel compounds as needed. With 25+ years of experience, TriLink is the industry‑leading provider of pseudouridines.
MT-943 - Form for page(s): request-a-gmp-reagents-consultation
TriLink operates an ISO 9001:2015 facility that helps ensure our chemically synthesized production materials for mRNA meet reported requirements for identity, quality, and purity. Our stringent quality systems and a dedicated team of quality experts ensure the highest level of consistency, purity, and comprehensive documentation.
Whether you require research use or GMP grade, TriLink offers over 150 modified nucleoside triphosphates to meet diverse application needs.